<DOC>
	<DOCNO>NCT02727751</DOCNO>
	<brief_summary>This phase 3 , open label study evaluate safety tenapanor 50 mg BID subject constipation-predominant irritable bowel syndrome ( IBS-C ) define ROME III criterion . Subjects complete either TEN-01-301 ( 16 week ) TEN-01-302 ( 26 week ) study may enrol . Subjects take tenapanor approximately 52-55 week total base previous protocol study .</brief_summary>
	<brief_title>A Long-Term Safety Study Tenapanor Treatment IBS-C</brief_title>
	<detailed_description>During treatment period 39-weeks , subject return study visit approximately every 13 week . Subjects undergo safety assessment visit , may include physical exam , ECG , vital sign , clinical lab . Adverse event concomitant medication record . Medication compliance monitor subject give additional study drug appropriate .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Subjects complete 16 week TEN01301 26 week TEN01302 Subject demonstrate adequate compliance study procedure either TEN01301 TEN01302 study Females must nonchildbearing potential ; If childbearing potential , must negative pregnancy test confirm use one appropriate mean contraception Males must agree use appropriate method barrier contraception document surgical sterilization Subject withdrawn discontinue prematurely either TEN01301 TEN01302 The subject report use prohibited medication willing abide restriction intake Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>